We work in disease areas with some of the greatest unmet need. We work relentlessly, knowing that bold new possibilities await discovery. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Company
Science & Innovation
Pūtaio & Hangarau
Disease Areas
The potential to transform the lives of people drives us at Biogen.
Alzheimer’s disease and dementia
Te Tuapaemahara & Te Matewareware
Our world-class neurology research and development organisation is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
Learn more
Multiple sclerosis (MS)
Te Mate Roro Tapepe
Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance treatments and improve outcomes for people with MS. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help pioneer new therapeutic solutions that may bring us closer to a cure for MS.
Learn more
Spinal muscular atrophy (SMA)
Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, Biogen launched a new collaboration with Ionis to identify new therapeutic options — specifically, new antisense oligonucleotide (ASO) candidates, which are designed to treat SMA — for individuals with this debilitating condition.